Calithera Biosciences (CALA) Competitors

Ampio Pharmaceuticals (NYSE:AMPE) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Is AMPE or CALA more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	N/A

Does the media refer more to AMPE or CALA?

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Calithera Biosciences	Neutral

Do insiders & institutionals believe in AMPE or CALA?

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has preferable valuation & earnings, AMPE or CALA?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	0.00
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Which has more volatility and risk, AMPE or CALA?

Ampio Pharmaceuticals has a beta of 4.69, meaning that its stock price is 369% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -2.77, meaning that its stock price is 377% less volatile than the S&P 500.

Summary

Ampio Pharmaceuticals beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks.